Virios Therapeutics, Inc. - VIRI STOCK NEWS

Virios Therapeutics (Nasdaq: VIRI) announced its Q2 2024 financial results and key developments. The Bateman Horne Center completed enrollment in a Long-COVID phase 2a study featuring valacyclovir and celecoxib (IMC-2), with top-line results expected in October 2024. The study's ongoing blinded safety analysis shows good tolerability. Virios completed a public offering with $1.7 million gross proceeds, extending its operational runway into Q1 2025.

Financial highlights for Q2 2024 include:

• R&D expenses: $0.3 million (down from $0.6 million in Q2 2023)
• G&A expenses: $0.7 million (down from $0.9 million in Q2 2023)
• Net loss: $1.0 million, or $0.05 per share (improved from $1.4 million, or $0.08 per share in Q2 2023)
• Cash balance as of June 30, 2024: $3.0 million

Virios Therapeutics (Nasdaq: VIRI), a development-stage biotech company, has announced it will release its second quarter 2024 financial results on Thursday, August 8, 2024, before the financial markets open. The company specializes in developing novel antiviral therapies for chronic conditions such as fibromyalgia and Long-COVID. This upcoming financial report will provide insights into Virios Therapeutics' financial performance and potentially its progress in advancing its therapeutic pipeline for these debilitating chronic diseases.

Virios Therapeutics (Nasdaq: VIRI) announced the completion of enrollment in a Phase 2 Long-COVID study for IMC-2, conducted by Bateman Horne Center. The study evaluates the combination of valacyclovir and celecoxib as a treatment for Long-COVID symptoms. Top line results are expected in October 2024.

The randomized, double-blind, placebo-controlled study follows a positive prior proof of concept study showing improvements in fatigue, pain, and other symptoms. Virios believes that activated herpes viruses may trigger or maintain Long-COVID and fibromyalgia. With an estimated 45 million potential adult patients affected by Long-COVID in the U.S., and no FDA-approved treatments available, Virios' antiviral combination could be a significant breakthrough.

Virios Therapeutics (Nasdaq: VIRI), a biotechnology company developing antiviral treatments for chronic diseases like fibromyalgia and Long-COVID, announced the closure of a $1.7 million public offering. The company sold 8.5 million shares at $0.20 each. The funds will support the IMC-2 Long-COVID Phase 2b study preparations and general corporate needs. Maxim Group was the sole placement agent. The offering was conducted under an effective shelf registration statement filed with the SEC.

This press release does not constitute a sales offer or solicitation in any jurisdiction where such activities are not legally sanctioned.

Virios Therapeutics announced the pricing of a $1.7 million public offering to fund its IMC-2 Long-COVID Phase 2b study.

The company will offer 8,500,000 shares at $0.20 per share, with the offering expected to close on May 22, 2024.

Maxim Group is acting as the sole placement agent. Gross proceeds are expected to be $1.7 million before deducting fees and expenses.

Net proceeds will be used for the Phase 2b study and general corporate purposes. The offering is made under an effective shelf registration statement filed with the SEC.

Virios Therapeutics (Nasdaq: VIRI), a biotechnology company focused on novel antiviral therapies, announced its intention to offer and sell up to $2.1 million in common stock.

Proceeds are earmarked for preparatory activities for the planned IMC-2 Long-COVID Phase 2b study and general corporate purposes.

The offering, subject to market conditions, is managed by Maxim Group as the sole placement agent.

The public offering will be made via an effective shelf registration statement filed with the SEC.

Virios Therapeutics, Inc. (Nasdaq: VIRI) announced financial results for Q1 2024 and a corporate update, highlighting the ongoing BHC-202 study for Long-COVID treatment with valacyclovir and celecoxib. Preliminary safety analysis shows positive results. The global patent for IMC-2 has been published. Discussions are in progress for IMC-1 Phase 3 development for FM. The company continues to seek strategic partnerships.

Virios Therapeutics, Inc. (Nasdaq: VIRI) will report its first quarter 2024 financial results on May 9, 2024. The company focuses on developing antiviral therapies for chronic diseases like fibromyalgia and Long-COVID. A webcast and conference call will be held to discuss the results and provide a corporate update.